Related Experiment Video
Updated: May 12, 2026

Murine Bilateral Renal Lymphadenectomy
Published on: December 30, 2025
Retroperitoneal amyloidosis as the presenting manifestation of Waldenstrom's macroglobulinaemia
Domingo Franco-Palacios1, Maher Tama, Suprotim Samaddar
1Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA. dfrancopalacios@gmail.com
Abstract:
Retroperitoneal amyloidosis has been described in a few case reports and is typically a secondary manifestation of inflammation or malignancy. We present the case of a 69-year-old man who presented with a large pleural effusion and an incidental retroperitoneal mass in the CT imaging. Further investigation confirmed the diagnosis of amyloid amyloidosis involving the retroperitoneum as well as a concurrent Waldenstrom's macroglobulinaemia. Chemotherapy consistent of drugs active against both the lymphoid and plasma cell components of the disease is the proposed therapy for Waldenstrom's macroglobulinaemia in those patients amenable to receive chemotherapy and can make a difference in the survival.
Insights
Retroperitoneal amyloidosis, a rare condition, was diagnosed alongside Waldenstrom
Area of Science:
- Oncology
- Nephrology
- Pathology
Background:
- Retroperitoneal amyloidosis is infrequently reported, often linked to inflammation or malignancy.
- Amyloidosis involves abnormal protein deposits in organs, potentially impairing function.
Observation:
- A 69-year-old male presented with a significant pleural effusion and an incidentally discovered retroperitoneal mass on CT scan.
- Diagnostic workup revealed amyloidosis affecting the retroperitoneum.
Findings:
- The patient was diagnosed with concurrent Waldenstrom's macroglobulinaemia, a lymphoproliferative disorder.
- Amyloid deposition was confirmed in the retroperitoneal tissues.
Implications:
- Chemotherapy targeting both lymphoid and plasma cell components offers a potential treatment strategy for Waldenstrom's macroglobulinaemia.
- This therapeutic approach may improve survival outcomes for affected patients.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
